Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)

Alexander C. Razavi, La Tonia C. Richardson, Fátima Coronado, Omar Dzaye, Harpreet S. Bhatia, Anurag Mehta, Arshed A. Quyyumi, Viola Vaccarino, Matthew J. Budoff, Khurram Nasir, Sotirios Tsimikas, Seamus P. Whelton, Michael J. Blaha, Roger S. Blumenthal, Laurence S. Sperling

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Lipoprotein(a) [Lp(a)] is an atherogenic and prothrombotic lipoprotein associated with atherosclerotic cardiovascular disease (ASCVD). We assessed the association between regular aspirin use and ASCVD mortality among individuals with versus without elevated Lp(a) in a nationally representative US cohort. Methods: Eligible participants were aged 40–70 years without clinical ASCVD, reported on aspirin use, and had Lp(a) measurements from the Third National Health and Nutrition Examination Survey (NHANES III, 1988–1994), the only cycle of this nationally representative US cohort to measure Lp(a). Regular aspirin use was defined as taking aspirin ≥30 times in the previous month. Using NHANES III linked mortality records and weighted Cox proportional hazards regression, the association between regular aspirin use and ASCVD mortality was observed in those with and without elevated Lp(a) (≥50 versus <50 mg/dL) over a median 26-year follow-up. Results: Among 2,990 persons meeting inclusion criteria (∼73 million US adults), the mean age was 50 years, 86% were non-Hispanic White, 9% were non-Hispanic Black, 53% were female, and 7% reported regular aspirin use. The median Lp(a) was 14 mg/dL and the proportion with elevated Lp(a) was similar among those with versus without regular aspirin use (15.1% versus 21.9%, p = 0.16). Among individuals with elevated Lp(a), the incidence of ASCVD mortality per 1,000 person-years was lower for those with versus without regular aspirin use (1.2, 95% CI: 0.1–2.3 versus 3.9, 95% CI: 2.8–4.9). In multivariable modeling, regular aspirin use was associated with a 52% lower risk of ASCVD mortality among individuals with elevated Lp(a) (HR=0.48, 95% CI: 0.28–0.83), but not for those without elevated Lp(a) (HR=1.01, 95% CI: 0.81–1.25; p-interaction=0.001). Conclusion: Regular aspirin use was associated with significantly lower ASCVD mortality in adults without clinical ASCVD who had elevated Lp(a). These findings may have clinical and public health implications for aspirin utilization in primary prevention.

Original languageEnglish (US)
Article number100674
JournalAmerican Journal of Preventive Cardiology
Volume18
DOIs
StatePublished - Jun 2024

Keywords

  • Aspirin
  • Cardiovascular disease
  • Lipoprotein(a)
  • NHANES

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)'. Together they form a unique fingerprint.

Cite this